{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:32:37Z","timestamp":1790728357992,"version":"4.1.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,6,4]],"date-time":"2018-06-04T00:00:00Z","timestamp":1528070400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s40262-018-0683-0","type":"journal-article","created":{"date-parts":[[2018,6,4]],"date-time":"2018-06-04T01:04:11Z","timestamp":1528074251000},"page":"299-308","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Therapeutic Drug Monitoring of Oral Anti-Hormonal Drugs in Oncology"],"prefix":"10.1007","volume":"58","author":[{"given":"Stefanie L.","family":"Groenland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merel","family":"van Nuland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remy B.","family":"Verheijen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan H. M.","family":"Schellens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos H.","family":"Beijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alwin D. R.","family":"Huitema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeltje","family":"Steeghs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,4]]},"reference":[{"key":"683_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2016;66:7\u201330.","journal-title":"CA Cancer J Clin."},{"key":"683_CR2","unstructured":"Committee for Medicinal Products for Human Use European Medicines Agency. Abiraterone European public assessment report. 2011. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002321\/WC500112858.pdf\n                    \n                  . Accessed 26 May 2018."},{"key":"683_CR3","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/cpt.787","volume":"102","author":"R Verheijen","year":"2017","unstructured":"Verheijen R, Yu H, Schellens J, Beijnen J, Steeghs N, Huitema A. Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology. Clin Pharmacol Ther. 2017;102:765\u201376.","journal-title":"Clin Pharmacol Ther."},{"key":"683_CR4","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s40262-014-0137-2","volume":"53","author":"H Yu","year":"2014","unstructured":"Yu H, Steeghs N, Nijenhuis C, Schellens J, Beijnen J, Huitema A. Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets. Clin Pharmacokinet. 2014;53:305\u201325.","journal-title":"Clin Pharmacokinet."},{"key":"683_CR5","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/clpt.2012.243","volume":"93","author":"JH Beumer","year":"2013","unstructured":"Beumer JH. Without therapeutic drug monitoring, there is no personalized cancer care. Clin Pharmacol Ther. 2013;93:228\u201330.","journal-title":"Clin Pharmacol Ther."},{"key":"683_CR6","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1016\/j.ejca.2014.04.014","volume":"50","author":"A Paci","year":"2014","unstructured":"Paci A, Veal G, Bardin C, Lev\u00eaque D, Widmer N, Beijnen J, et al. Review of therapeutic drug monitoring of anticancer drugs part 1: cytotoxics. Eur J Cancer. 2014;50:2010\u20139.","journal-title":"Eur J Cancer."},{"key":"683_CR7","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1016\/j.ejca.2014.04.015","volume":"50","author":"N Widmer","year":"2014","unstructured":"Widmer N, Bardin C, Chatelut E, Paci A, Beijnen J, Lev\u00eaque D, et al. Review of therapeutic drug monitoring of anticancer drugs part two: targeted therapies. Eur J Cancer. 2014;50:2020\u201336.","journal-title":"Eur J Cancer."},{"key":"683_CR8","doi-asserted-by":"publisher","first-page":"3164","DOI":"10.1158\/1078-0432.CCR-15-1470","volume":"22","author":"P Fox","year":"2016","unstructured":"Fox P, Balleine RL, Lee C, Gao B, Balakrishnar B, Menzies AM, et al. Dose escalation of tamoxifen in patients with low endoxifen level: evidence for therapeutic drug monitoring: the TADE study. Clin Cancer Res. 2016;22:3164\u201371.","journal-title":"Clin Cancer Res."},{"key":"683_CR9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.drudis.2014.09.007","volume":"20","author":"D Wit De","year":"2015","unstructured":"De Wit D, Guchelaar HJ, Den Hartigh J, Gelderblom H, Van Erp NP. Individualized dosing of tyrosine kinase inhibitors: are we there yet? Drug Discov Today. 2015;20:18\u201336.","journal-title":"Drug Discov Today."},{"key":"683_CR10","unstructured":"US Food and Drug Administration. Center for Drug Evaluation and Research. Abiraterone clinical pharmacology and biopharmaceutics review. 2011. \n                    http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/202379Orig1s000ClinPharmR.pdf\n                    \n                  . Accessed 26 May 2018."},{"key":"683_CR11","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","volume":"377","author":"ND James","year":"2017","unstructured":"James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377:338\u201351.","journal-title":"N Engl J Med."},{"key":"683_CR12","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1002\/jcph.564","volume":"55","author":"KN Chi","year":"2015","unstructured":"Chi KN, Spratlin J, Kollmannsberger C, North S, Pankras C, Gonzalez M, et al. Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer. J Clin Pharmacol. 2015;55:1406\u201314.","journal-title":"J Clin Pharmacol."},{"key":"683_CR13","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ejca.2016.11.027","volume":"72","author":"E Carton","year":"2017","unstructured":"Carton E, Noe G, Huillard O, Golmard L, Giroux J, Cessot A, et al. Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients. Eur J Cancer. 2017;72:54\u201361.","journal-title":"Eur J Cancer."},{"key":"683_CR14","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s40262-014-0178-6","volume":"53","author":"K Stuyckens","year":"2014","unstructured":"Stuyckens K, Saad F, Xu XS, Ryan CJ, Smith MR, Griffin TW, et al. Population pharmacokinetic analysis of abiraterone in chemotherapy-na\u00efve and docetaxel-treated patients with metastatic castration-resistant prostate cancer. Clin Pharmacokinet. 2014;53:1149\u201360.","journal-title":"Clin Pharmacokinet."},{"key":"683_CR15","doi-asserted-by":"publisher","first-page":"4563","DOI":"10.1200\/JCO.2007.15.9749","volume":"26","author":"G Attard","year":"2008","unstructured":"Attard G, Reid AHM, Yap TA, Raynaud F, Dowsett M, Settatree S, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008;26:4563\u201371.","journal-title":"J Clin Oncol."},{"key":"683_CR16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s40262-016-0425-0","volume":"56","author":"X Steven","year":"2017","unstructured":"Steven X, Charles X, Kim JR, Matthew S, Saad F, Griffin TW, et al. Modeling the relationship between exposure to abiraterone and prostate-specific antigen dynamics in patients with metastatic castration-resistant prostate cancer. Clin Pharmacokinet. 2017;56:55\u201363.","journal-title":"Clin Pharmacokinet."},{"key":"683_CR17","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nature14406","volume":"523","author":"Z Li","year":"2015","unstructured":"Li Z, Bishop AC, Alyamani M, Garcia JA, Dreicer R, Bunch D, et al. Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer. Nature. 2015;523:347\u201351.","journal-title":"Nature."},{"key":"683_CR18","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1080\/15384101.2015.1086201","volume":"14","author":"H Emamekhoo","year":"2015","unstructured":"Emamekhoo H, Li Z, Sharifi N. Clinical significance of D4A in prostate cancer therapy with abiraterone. Cell Cycle. 2015;14:3213\u20134.","journal-title":"Cell Cycle."},{"key":"683_CR19","unstructured":"US Food and Drug Administration. Center for Drug Evaluation and Research. Enzalutamide clinical pharmacology and biopharmaceutics review. 2012. \n                    http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203415Orig1s000ClinPharmR.pdf\n                    \n                  . Accessed 26 May 2018."},{"key":"683_CR20","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s40262-015-0271-5","volume":"54","author":"JA Gibbons","year":"2015","unstructured":"Gibbons JA, Ouatas T, Krauwinkel W, Ohtsu Y, van der Walt J-S, Beddo V, et al. Clinical pharmacokinetic studies of enzalutamide. Clin Pharmacokinet. 2015;54:1043\u201355.","journal-title":"Clin Pharmacokinet."},{"key":"683_CR21","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/S0140-6736(10)60172-9","volume":"375","author":"HI Scher","year":"2010","unstructured":"Scher HI, Anand A, Rathkopf D, Shelkey J, Morris MJ, Danila DC, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010;375:1437\u201346.","journal-title":"Lancet."},{"key":"683_CR22","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1002\/cncr.30587","volume":"123","author":"AJ Armstrong","year":"2017","unstructured":"Armstrong AJ, Saad F, Phung D, Dmuchowski C, Shore ND, Fizazi K, et al. Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel. Cancer. 2017;123:2303\u201311.","journal-title":"Cancer."},{"key":"683_CR23","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s40262-015-0273-3","volume":"54","author":"AHM Vries Schultink de","year":"2015","unstructured":"de Vries Schultink AHM, Zwart W, Linn SC, Beijnen JH, Huitema ADR. Effects of pharmacogenetics on the pharmacokinetics and pharmacodynamics of tamoxifen. Clin Pharmacokinet. 2015;54:797\u2013810.","journal-title":"Clin Pharmacokinet."},{"key":"683_CR24","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s10549-013-2826-1","volume":"143","author":"NGL Jager","year":"2014","unstructured":"Jager NGL, Rosing H, Schellens JHM, Linn SC, Beijnen JH. Tamoxifen dose and serum concentrations of tamoxifen and six of its metabolites in routine clinical outpatient care. Breast Cancer Res Treat. 2014;143:477\u201383.","journal-title":"Breast Cancer Res Treat."},{"key":"683_CR25","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.clpt.2006.03.013","volume":"80","author":"S Borges","year":"2006","unstructured":"Borges S, Desta Z, Li L, Skaar TC, Ward BA, Nguyen A, et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther. 2006;80:61\u201374.","journal-title":"Clin Pharmacol Ther."},{"key":"683_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/clpt.2011.27","volume":"89","author":"TE M\u00fcrdter","year":"2011","unstructured":"M\u00fcrdter TE, Schroth W, Bacchus-Gerybadze L, Winter S, Heinkele G, Simon W, et al. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther. 2011;89:1\u201310.","journal-title":"Clin Pharmacol Ther."},{"key":"683_CR27","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1186\/1471-2407-13-612","volume":"13","author":"N Jager","year":"2013","unstructured":"Jager N, Koornstra R, Vincent A, van Schaik R, Huitema A, Korse C, et al. Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites. BMC Cancer. 2013;13:612.","journal-title":"BMC Cancer."},{"key":"683_CR28","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/clpt.2011.32","volume":"89","author":"L Madlensky","year":"2011","unstructured":"Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, Flatt SW, et al. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther. 2011;89:718\u201325.","journal-title":"Clin Pharmacol Ther."},{"issue":"3","key":"683_CR29","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s10549-016-4083-6","volume":"161","author":"AHM Vries Schultink de","year":"2017","unstructured":"de Vries Schultink AHM, Alexi X, van Werkhoven E, Madlensky L, Natarajan L, Flatt SW, et al. An antiestrogenic activity score for tamoxifen and its metabolites is associated with breast cancer outcome. Breast Cancer Res Treat. 2017;161(3):567\u201374.","journal-title":"Breast Cancer Res Treat."},{"issue":"10","key":"683_CR30","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1158\/1078-0432.CCR-17-3028","volume":"24","author":"P Neven","year":"2018","unstructured":"Neven P, Jongen L, Lintermans A, Van Asten K, Blomme C, Lambrechts D, et al. Tamoxifen metabolism and efficacy in breast cancer: a prospective multicentre trial. Clin Cancer Res. 2018;24(10):2312\u20138.","journal-title":"Clin Cancer Res."},{"key":"683_CR31","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/jnci\/dji005","volume":"97","author":"Y Jin","year":"2005","unstructured":"Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005;97:30\u20139.","journal-title":"J Natl Cancer Inst."},{"issue":"Suppl.","key":"683_CR32","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1200\/jco.2011.29.15_suppl.562","volume":"15","author":"V Dezentje","year":"2011","unstructured":"Dezentje V, den Hartigh J, Guchelaar H, Hessing T, van der Straaten T, Vletter-Bogaartz J. Association between endoxifen serum concentration and predicted CYP2D6 phenotype in a prospective cohort of patients with early-stage breast cancer. J Clin Oncol. 2011;15(Suppl.):562.","journal-title":"J Clin Oncol."},{"key":"683_CR33","unstructured":"US Food and Drug Administration. Center for Drug Evaluation and Research. Anastrozole clinical pharmacology and biopharmaceutics review. 2000. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2000\/20-541S006_Arimidex_biopharmr.pdf\n                    \n                  . Accessed 26 May 2018."},{"key":"683_CR34","unstructured":"US Food and Drug Administration. Center for Drug Evaluation and Research. Letrozole clinical pharmacology and biopharmaceutics review. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/97\/20726_FEMARA\n                    \n                   2.5MG_BIOPHARMR.PDF. Accessed 26 May 2018."},{"key":"683_CR35","unstructured":"US Food and Drug Administration. Center for Drug Evaluation and Research. Exemestane clinical pharmacology and biopharmaceutics review. 1999. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/99\/20-753_Aromasin_biopharmr_P1.pdf\n                    \n                  . Accessed 26 May 2018."},{"key":"683_CR36","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1517\/14740338.2010.515977","volume":"9","author":"CM Kelly","year":"2010","unstructured":"Kelly CM, Buzdar AU. Anastrozole. Expert Opin Drug Saf. 2010;9:995\u20131003.","journal-title":"Expert Opin Drug Saf."},{"key":"683_CR37","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1200\/JCO.2012.46.2622","volume":"31","author":"S Pauwels","year":"2013","unstructured":"Pauwels S, Lintermans A, Neven P, Verhaeghe J, Jans I, Billen J, et al. Need for estradiol assays with a lower functional sensitivity in clinical studies examining postmenopausal women treated with aromatase inhibitors. J Clin Oncol. 2013;31:509.","journal-title":"J Clin Oncol."},{"key":"683_CR38","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.steroids.2014.08.009","volume":"99","author":"H Ketha","year":"2015","unstructured":"Ketha H, Girtman A, Singh RJ. Estradiol assays: the path ahead. Steroids. 2015;99:39\u201344.","journal-title":"Steroids."},{"key":"683_CR39","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1158\/0008-5472.CAN-09-3024","volume":"70","author":"JN Ingle","year":"2010","unstructured":"Ingle JN, Buzdar AU, Schaid DJ, Goetz MP, Batzler A, Robson ME, et al. Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer. Cancer Res. 2010;70:3278\u201386.","journal-title":"Cancer Res."},{"key":"683_CR40","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1200\/JCO.2012.42.0273","volume":"30","author":"EJ Folkerd","year":"2012","unstructured":"Folkerd EJ, Dixon JM, Renshaw L, A\u2019Hern RP, Dowsett M. Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. J Clin Oncol. 2012;30:2977\u201380.","journal-title":"J Clin Oncol."},{"key":"683_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-016-3022-6","volume":"17","author":"A Oberguggenberger","year":"2017","unstructured":"Oberguggenberger A, Meraner V, Sztankay M, Beer B, Weigel G, Oberacher H, et al. Can we use gonadotropin plasma concentration as surrogate marker for BMI-related incomplete estrogen suppression in breast cancer patients receiving anastrozole? BMC Cancer. 2017;17:1\u20137.","journal-title":"BMC Cancer."},{"key":"683_CR42","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.steroids.2014.08.007","volume":"99","author":"JN Ingle","year":"2015","unstructured":"Ingle JN, Kalari KR, Buzdar AU, Robson ME, Goetz MP, Desta Z, et al. Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole. Steroids. 2015;99:32\u20138.","journal-title":"Steroids."},{"key":"683_CR43","first-page":"1890","volume":"4","author":"F Micheal","year":"2012","unstructured":"Micheal F, Saranya S, Aparna N, Sridevi N, Chithra R, Judith MP. Concepts of bioequivalence and its impact on truncated area under curve (AUC) of drugs with long half life in point estimate and intra-subject variability. J Pharm Sci Res. 2012;4:1890\u20136.","journal-title":"J Pharm Sci Res."},{"key":"683_CR44","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/BF00682745","volume":"30","author":"P Plourde","year":"1994","unstructured":"Plourde P, Dyroff M, Dukes M. Arimidex: a potent and selective fourth-generation aromatase inhibitor. Breast Cancer Res Treat. 1994;30:103\u201311.","journal-title":"Breast Cancer Res Treat."},{"key":"683_CR45","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1038\/bjc.1996.531","volume":"74","author":"J Geisler","year":"1996","unstructured":"Geisler J, King N, Dowsett M, Ottestad L, Lundgren S, Walton P, et al. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer. 1996;74:1286\u201391.","journal-title":"Br J Cancer."},{"issue":"3","key":"683_CR46","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1177\/0004563216674031","volume":"54","author":"S Mandic","year":"2017","unstructured":"Mandic S, Kratzsch J, Mandic D, Debeljak Z, Lukic I, Horvat V, et al. Falsely elevated serum oestradiol due to exemestane therapy. Ann Clin Biochem. 2017;54(3):402\u20135.","journal-title":"Ann Clin Biochem."},{"issue":"6","key":"683_CR47","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/tpj.2016.60","volume":"17","author":"DL Hertz","year":"2017","unstructured":"Hertz DL, Kidwell KM, Seewald NJ, Gersch CL, Desta Z, Flockhart DA, et al. Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer. Pharmacogenom J. 2017;17(6):521\u20137.","journal-title":"Pharmacogenom J."},{"issue":"3","key":"683_CR48","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s10549-017-4346-x","volume":"165","author":"DL Hertz","year":"2017","unstructured":"Hertz DL, Speth KA, Kidwell KM, Gersch CL, Desta Z, Storniolo AM, et al. Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients. Breast Cancer Res Treat. 2017;165(3):659\u201368.","journal-title":"Breast Cancer Res Treat."},{"key":"683_CR49","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1097\/FTD.0b013e3181b2c8cf","volume":"31","author":"Y Wang","year":"2009","unstructured":"Wang Y, Chia Y, Nedelman J, Schran H, Mahon F, Molimard M. A therapeutic drug monitoring algorithm for refining the imatinib trough level obtained at different sampling times. Ther Drug Monit. 2009;31:579\u201384.","journal-title":"Ther Drug Monit."},{"key":"683_CR50","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/clpt.2011.174","volume":"90","author":"Z Desta","year":"2011","unstructured":"Desta Z, Kreutz Y, Nguyen AT, Li L, Skaar T, Kamdem LK, et al. Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age. Clin Pharmacol Ther. 2011;90:693\u2013700.","journal-title":"Clin Pharmacol Ther."},{"key":"683_CR51","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2165\/00003088-200544020-00002","volume":"44","author":"ME Jonge De","year":"2005","unstructured":"De Jonge ME, Huitema ADR, Schellens JHM, Rodenhuis S, Beijnen JH. Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review. Clin Pharmacokinet. 2005;44:147\u201373.","journal-title":"Clin Pharmacokinet."},{"key":"683_CR52","unstructured":"US Food and Drug Administration. Center for Drug Evaluation and Research. Guidance for industry: exposure\u2013response relationships: study design, data analysis and regulatory applications. FDA Guide. 2003;1\u201325. \n                    https:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm072109.pdf\n                    \n                  ."},{"key":"683_CR53","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/FTD.0000000000000387","volume":"39","author":"M Nuland van","year":"2017","unstructured":"van Nuland M, Hillebrand MJX, Rosing H, Schellens JHM, Beijnen JH. Development and validation of an LC\u2013MS\/MS method for the simultaneous quantification of abiraterone, enzalutamide, and their major metabolites in human plasma. Ther Drug Monit. 2017;39:243\u201351.","journal-title":"Ther Drug Monit."},{"key":"683_CR54","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1097\/FTD.0000000000000372","volume":"39","author":"S Krou de","year":"2017","unstructured":"de Krou S, Rosing H, Nuijen B, Schellens JHM, Beijnen JH. Fast and adequate liquid chromatography-tandem mass spectrometric determination of Z-endoxifen serum levels for terapeutic drug monitoring. Ther Drug Monit. 2017;39:132\u20137.","journal-title":"Ther Drug Monit."},{"key":"683_CR55","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jchromb.2017.10.033","volume":"1068\u201310699","author":"M Nuland van","year":"2017","unstructured":"van Nuland M, Rosing H, de Vries J, Ovaa H, Schellens JHM, Beijnen JH. An LC\u2013MS\/MS method for quantification of the active abiraterone metabolite \u0394(4)-abiraterone (D4A) in human plasma. J Chromatogr B Anal Technol Biomed Life Sci. 2017;1068\u201310699:119\u201324.","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci."},{"key":"683_CR56","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/bmc.3607","volume":"30","author":"R Shao","year":"2016","unstructured":"Shao R, Yu L, Lou H, Ruan Z, Jiang B, Chen J. Development and validation of a rapid LC\u2013MS\/MS method to quantify letrozole in human plasma and its application to therapeutic drug monitoring. Biomed Chromatogr. 2016;30:632\u20137.","journal-title":"Biomed Chromatogr."},{"key":"683_CR57","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/bmc.1476","volume":"25","author":"J Yu","year":"2011","unstructured":"Yu J, He J, Zhang Y, Qin F, Xiong Z, Li F. Development of a liquid chromatography\u2013tandem mass spectrometry method for determination of butoconazole nitrate in human plasma and its application to a pharmacokinetic study. Biomed Chromatogr. 2011;25:511\u20136.","journal-title":"Biomed Chromatogr."},{"issue":"3","key":"683_CR58","doi-asserted-by":"publisher","first-page":"e0118553","DOI":"10.1371\/journal.pone.0118553","volume":"10","author":"L-Z Wang","year":"2015","unstructured":"Wang L-Z, Goh S-H, Wong AL-A, Thuya W-L, Lau J-YA, Wan S-C, et al. Validation of a rapid and sensitive LC\u2013MS\/MS method for determination of exemestane and its metabolites, 17beta-hydroxyexemestane and 17beta-hydroxyexemestane-17-O-beta-d-glucuronide: application to human pharmacokinetics study. PLoS One. 2015;10(3):e0118553.","journal-title":"PLoS One."},{"issue":"1","key":"683_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40262-017-0571-z","volume":"57","author":"E Cardoso","year":"2018","unstructured":"Cardoso E, Csajka C, Schneider MP, Widmer N. Effect of adherence on pharmacokinetic\/pharmacodynamic relationships of oral targeted anticancer drugs. Clin Pharmacokinet. 2018;57(1):1\u20136.","journal-title":"Clin Pharmacokinet."},{"key":"683_CR60","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/bcp.13130","volume":"83","author":"G Gervasini","year":"2017","unstructured":"Gervasini G, Jara C, Olier C, Romero N, Martinez R, Carrillo JA. Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients. Br J Clin Pharmacol. 2017;83:562\u201371.","journal-title":"Br J Clin Pharmacol."},{"key":"683_CR61","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1054\/bjoc.2001.1925","volume":"85","author":"M Dowsett","year":"2001","unstructured":"Dowsett M, Cuzick J, Howell A. Jackson I; ATAC Trialists\u2019 Group. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the \u201cArimidex\u2122 and tamoxifen alone or in combination\u201d (ATAC) trial. Br J Cancer. 2001;85:317\u201324.","journal-title":"Br J Cancer."},{"key":"683_CR62","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.clbc.2013.12.008","volume":"14","author":"M Hubalek","year":"2014","unstructured":"Hubalek M, Oberguggenberger A, Beer B, Meraner V, Sztankay M, Oberacher H, et al. Does obesity interfere with anastrozole treatment? Positive association between body mass index and anastrozole plasma levels. Clin Breast Cancer. 2014;14:291\u20136.","journal-title":"Clin Breast Cancer."},{"key":"683_CR63","unstructured":"Committee for Medicinal Products for Human Use European Medicines Agency. Public assessment report: scientific discussion exemestane. 2010. \n                    https:\/\/db.cbg-meb.nl\/Pars\/h104327.pdf%0A\n                    \n                  . Accessed 26 May 2018."},{"key":"683_CR64","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1093\/oxfordjournals.annonc.a010490","volume":"7","author":"G Bisagni","year":"1996","unstructured":"Bisagni G, Cocconi G, Scaglione F, Fraschini F, Pfister C, Trunet PF. Letrozole, a new oral non-steroidal aromatase inhibitor in treating postmenopausal patients with advanced breast cancer: a pilot study. Ann Oncol. 1996;7:99\u2013102.","journal-title":"Ann Oncol"},{"key":"683_CR65","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s10549-015-3452-x","volume":"152","author":"L Binkhorst","year":"2015","unstructured":"Binkhorst L, Kloth JSL, de Wit AS, de Bruijn P, Lam MH, Chaves I, et al. Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients. Breast Cancer Res Treat. 2015;152:119\u201328.","journal-title":"Breast Cancer Res Treat."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-018-0683-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-018-0683-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-018-0683-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T16:12:15Z","timestamp":1568736735000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-018-0683-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,4]]},"references-count":65,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["683"],"URL":"https:\/\/doi.org\/10.1007\/s40262-018-0683-0","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,4]]},"assertion":[{"value":"4 June 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No funding was received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Remy B. Verheijen is currently a full-time employee of AstraZeneca, Cambridge, UK. Although Jan H. M. Schellens is involved in Modra Pharmaceuticals, this article does not contain information that poses a conflict of interest as it does not examine any product of Modra Pharmaceuticals or products related to this spinout company. Stefanie L. Groenland, Merel van Nuland, Jos H. Beijnen, Alwin D. R. Huitema, and Neeltje Steeghs have no conflicts of interest directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}